Anavex Life Sciences Presents New Information on Its Alzheimer’s Therapy Anavex 2-73

Anavex Life Sciences Presents New Information on Its Alzheimer’s Therapy Anavex 2-73
Anavex Life Sciences  has presented new information at a New York conference on Anavex 2-73, which prevented further decline in Alzheimer's patients' mental capacity in a clinical trial last year. Dr. Christopher U. Missling, Anavex’s president and chief executive officer, made the presentation at the Jefferies 2017 Global Healthcare Conference in New York City on June 9. Anavex 2-73 addresses the misfolded proteins involved in several neurodegenerative diseases,  including Alzheimer's. It prompts the sigma-1 and M1 muscarinic receptors to help cells clear misfolded proteins. In preclinical-trial studies before the Phase 2a trial, the company said Anavex 2-73 prevented, stopped, and even reversed Alzheimer's. In November 2016, the company reported that Anavex 2-73 prevented further decline in mental capacity in 32 people with mild to moderate Alzheimer's. The objectives of the Phase 2a study (NCT02244541) were to establish the safety and the maximum dose of Anavex 2-73 that patients could tolerate. During the 41 weeks of treatment, oral doses ranging from 30 mg to 50 mg were well-tolerated, without causing adverse reactions. Two of the trial's secondary objectives were seeing how patients would respond to each dose level and determining whether the therapy could improve cognitive function. Another objective was to determine the drug's b
Subscribe or to access all post and page content.